Who are Benadryl demand's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): olopatadine (OLO), Atarax (Hydroxyzine), diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, Fluticasone/Azelastine nasal spray, Olopatadine Nasal Spray, alcaftadine 0.25% ophthalmic solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/benadryl-demand.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Benadryl demand — Competitive Intelligence Brief

Benadryl demand (Benadryl demand) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: First-generation H1 antihistamine. Area: Allergy/Immunology.

marketed First-generation H1 antihistamine H1 histamine receptor Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Benadryl demand (Benadryl demand) — University of Pennsylvania. Benadryl (diphenhydramine) is a first-generation antihistamine that blocks H1 histamine receptors to reduce allergic and inflammatory responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Benadryl demand TARGET	Benadryl demand	University of Pennsylvania	marketed	First-generation H1 antihistamine	H1 histamine receptor
olopatadine (OLO)	olopatadine (OLO)	University of Chicago	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
Atarax (Hydroxyzine)	Atarax (Hydroxyzine)	University Hospital, Toulouse	marketed	First-generation H1 antihistamine	H1 histamine receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)
Fluticasone/Azelastine nasal spray	Fluticasone/Azelastine nasal spray	University of Chicago	marketed	Intranasal corticosteroid/antihistamine combination	Glucocorticoid receptor; H1 histamine receptor
Olopatadine Nasal Spray	Olopatadine Nasal Spray	ORA, Inc.	marketed	Selective H1-receptor antagonist / mast cell stabilizer	H1 histamine receptor
alcaftadine 0.25% ophthalmic solution	alcaftadine 0.25% ophthalmic solution	Allergan	marketed	Selective H1-receptor antagonist	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (First-generation H1 antihistamine class)

National Cancer Institute (NCI) · 1 drug in this class
University Hospital, Toulouse · 1 drug in this class
University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Benadryl demand — Competitive Intelligence Brief. https://druglandscape.com/ci/benadryl-demand. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab